Abstract

Two new mixed-ligand-based compounds, namely [Co(1,3-pde)(4-bpmh)]_n (1) and [Zn₃(3,3’-bpdc)₃(4-bpmh)_1.5]_n (2) (1,3-H₂pde = 1,3-phenylenediacetic acid, 3,3’-H₂bpdc = biphenyl-3,3'-dicarboxylic acid, 4-bpmh = N,N-bis-pyridin-4-ylmethylene-hydrazine) have been prepared under hydrothermal conditions. The obtained compounds were determined by singe crystalX-ray diffraction analyses, elemental analyses, powder X-ray diffraction analyses and thermogravimetric analyses. Moreover, the photocatalytic activity of 1 and luminescent property of 2 have also been investigated. This presented research estimate their treatment activity of the polycystic ovary syndrome, also the mechanism was measured as well. Firstly, a relative expression of the estrogen receptor on the ovarian epithelial cells was determined with real time RT-PCR. In addition, the amount of progesterone of the plasma was measured with ELISA detection kit after indicated treatment.

摘要

两种新的基于混合配体的化合物，即[Co（1,3-pde）（4-bpmh）] _n（1）和[Zn ₃（3,3'-bpdc）₃（4-bpmh）_1.5 ] _n（2）（1,3-H ₂ pde = 1,3-苯二乙酸，3,3'-H ₂ bpdc =联苯-3,3'-二羧酸，4-bpmh = N，N-双吡啶- 4-基亚甲基-肼）是在水热条件下制备的。通过单晶X射线衍射分析，元素分析，粉末X射线衍射分析和热重分析来确定所获得的化合物。另外，光催化活性为1，发光性能为2也已被调查。本研究估计了它们对多囊卵巢综合征的治疗活性，并对其作用机理进行了测定。首先，通过实时RT-PCR确定雌激素受体在卵巢上皮细胞上的相对表达。另外，在指定治疗后，用ELISA检测试剂盒测量血浆中的孕酮量。